Martín González-Andrade

Dr. Martín González-Andrade

Faculty of Medicine, UNAM
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
DMDeyamira Matuz-Mares
Deyamira Matuz-Mares
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
MAMinerva Georgina Araiza Araiza-Villanueva
Minerva Georgina Araiza Araiza-Villanueva
MVMaría Magdalena Nacional Autónoma Vilchis-Landeros
María Magdalena Nacional Autónoma Vilchis-Landeros
HMHECTOR VAZQUEZ MEZA
HECTOR VAZQUEZ MEZA
Calcium is used in many cellular processes and is maintained within the cell as free calcium at low concentrations (approximately 100 nM), compared with extracellular (millimolar) concentrations, to avoid adverse effects such as phosphate precipitation. For this reason, cells have adapted buffering strategies by compartmentalizing calcium into mitochondria and the endoplasmic reticulum (ER). In mitochondria, the calcium concentration is in the millimolar range, as it is in the ER. Mitochondria actively contribute to buffering cellular calcium, but if matrix calcium increases beyond physiological demands, it can promote the opening of the mitochondrial permeability transition pore (mPTP) and, consequently, trigger apoptotic or necrotic cell death. The pathophysiological implications of mPTP opening in ischemia-reperfusion, liver, muscle, and lysosomal storage diseases, as well as those affecting the central nervous system, for example, Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) have been reported. In this review, we present an updated overview of the main cellular mechanisms of mitochondrial calcium regulation. We specially focus on neurodegenerative diseases related to imbalances in calcium homeostasis and summarize some proposed therapies studied to attenuate these diseases.

15 May 2012 in Journal of Natural Products
Verified
Journal Article
Closed access
SRSONIA MARLEN ESCANDON RIVERA
SONIA MARLEN ESCANDON RIVERA
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
RBRobert Bye
Robert Bye
ELEdelmira Linares
Edelmira Linares
ANAndrés Navarrete
Andrés Navarrete
Rachel MataRachel Mata
Rachel Mata

29 September 2010 in Journal of Natural Products
Verified
Journal Article
Closed access
FBFernando Brindis
Fernando Brindis
RRRogelio Rodríguez
Rogelio Rodríguez
RBRobert Bye
Robert Bye
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
RMRachel Mata
Rachel Mata

19 April 2017 in Journal of Natural Products
Verified
Journal Article
Closed access
LFLaura Flores-Bocanegra
Laura Flores-Bocanegra
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
RBRobert Bye
Robert Bye
ELEdelmira Linares
Edelmira Linares
Rachel MataRachel Mata
Rachel Mata

9 May 2024 in FEBS Letters
Verified
Journal Article
Open access
ACAndrea Coronell‐Tovar
Andrea Coronell‐Tovar
JPJuan P. Pardo
Juan P. Pardo
ARAdela Rodriguez-Romero
Adela Rodriguez-Romero
ASAlejandro Sosa‐Peinado
Alejandro Sosa‐Peinado
LVLuz Vásquez‐Bochm
Luz Vásquez‐Bochm
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
Tyrosine protein phosphatase non‐receptor type 1 (PTP1B; also known as protein tyrosine phosphatase 1B) is a member of the protein tyrosine phosphatase (PTP) family and is a soluble enzyme that plays an essential role in different physiological processes, including the regulation of metabolism, specifically in insulin and leptin sensitivity. PTP1B is crucial in the pathogenesis of type 2 diabetes mellitus and obesity. These biological functions have made PTP1B validated as an antidiabetic and anti‐obesity, and potentially anticancer, molecular target. Four main approaches aim to inhibit PTP1B: orthosteric, allosteric, bidentate inhibition, and PTPN1 gene silencing. Developing a potent and selective PTP1B inhibitor is still challenging due to the enzyme's ubiquitous expression, subcellular location, and structural properties. This article reviews the main advances in the study of PTP1B since it was first isolated in 1988, as well as recent contextual information related to the PTP family to which this protein belongs. Furthermore, we offer an overview of the role of PTP1B in diabetes and obesity, and the challenges to developing selective, effective, potent, bioavailable, and cell‐permeable compounds that can inhibit the enzyme.

16 May 2017 in Analytical Chemistry
Verified
Journal Article
Closed access
RPRiikka Peltomaa
Riikka Peltomaa
Elena Benito PeñaElena Benito Peña
Elena Benito Peña
RBRodrigo Barderas
Rodrigo Barderas
USUrsula Sauer
Ursula Sauer
Martín González-AndradeMartín González-Andrade
Martín González-Andrade
Maria C Moreno-BondiMaria C Moreno-Bondi
Maria C Moreno-Bondi